News Releases

Date	Title	View
October 9, 2026	Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures	PDF Version
September 4, 2026	Alumis to Participate in Upcoming September Investor Conferences	PDF Version
September 1, 2026	Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)	PDF Version
August 13, 2026	Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements	PDF Version
August 10, 2026	Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies	PDF Version
May 14, 2026	Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements	PDF Version
March 28, 2026	Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis	PDF Version
March 19, 2026	Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements	PDF Version
March 18, 2026	Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting	PDF Version
March 2, 2026	Alumis to Present at the Leerink Partners Global Healthcare Conference	PDF Version